Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 3;22(1):721.
doi: 10.1186/s12879-022-07696-6.

Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study

Collaborators, Affiliations

Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study

Concepción Violán et al. BMC Infect Dis. .

Abstract

Background: Understanding the immune response to the SARS-CoV-2 virus is critical for efficient monitoring and control strategies. The ProHEpic-19 cohort provides a fine-grained description of the kinetics of antibodies after SARS-CoV-2 infection with an exceptional resolution over 17 months.

Methods: We established a cohort of 769 healthcare workers including healthy and infected with SARS-CoV-2 in northern Barcelona to determine the kinetics of the IgM against the nucleocapsid (N) and the IgG against the N and spike (S) of SARS-CoV-2 in infected healthcare workers. The study period was from 5 May 2020 to 11 November 2021.We used non-linear mixed models to investigate the kinetics of IgG and IgM measured at nine time points over 17 months from the date of diagnosis. The model included factors of time, gender, and disease severity (asymptomatic, mild-moderate, severe-critical) to assess their effects and their interactions.

Findings: 474 of the 769 participants (61.6%) became infected with SARS-CoV-2. Significant effects of gender and disease severity were found for the levels of all three antibodies. Median IgM(N) levels were already below the positivity threshold in patients with asymptomatic and mild-moderate disease at day 270 after the diagnosis, while IgG(N and S) levels remained positive at least until days 450 and 270, respectively. Kinetic modelling showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay with a rate depending on disease severity. IgG(S) levels remained relatively constant from day 15 over time.

Interpretation: IgM(N) and IgG(N, S) SARS-CoV-2 antibodies showed a heterogeneous kinetics over the 17 months. Only the IgG(S) showed a stable increase, and the levels and the kinetics of antibodies varied according to disease severity. The kinetics of IgM and IgG observed over a year also varied by clinical spectrum can be very useful for public health policies around vaccination criteria in adult population.

Funding: Regional Ministry of Health of the Generalitat de Catalunya (Call COVID19-PoC SLT16_04; NCT04885478).

Keywords: Antibodies; COVID-19; Clinical spectrum; Cohort; Health care workers; Humoral immunity; IgG; IgM; Kinetics; Non-linear mixed models; SARS-CoV-2; Seroprevalence.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare no support from any organization for the submitted work other than that detailed in the Funding section. All other authors declare no have no competing interests as defined by BMC, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Figures

Fig. 1
Fig. 1
IgM (N), IgG (N) ang IgG(S) levels, by days since diagnosis. Antibody levels are represented with a boxplot together with a dot and text describing their mean value. The dashed and the solid horizontal lines represent the uncertainty and positivity thresholds, respectively. AC show the significant differences in the median antibody levels between days. DF show significant differences in the median antibody levels across disease severity at each timepoint. Finally, GI show the significant differences in antibody levels between genders at each timepoint. Significance levels were reported as: * for p-value ≤ 0.05; ** for p-value ≤ 0.01; *** for p-value ≤ 0.001; and **** for p-value ≤ 0.0001
Fig. 2
Fig. 2
Kinetics of IgM(N), IgG(N) and IgG(S) levels since diagnosis in the total sample and stratified by disease severity. A, C and E show the LOESS regression models, connecting datapoints belonging to the same participants. B, D and F show the estimated non-linear mixed-effect (NLME) model curves. Each point corresponds to the mean value at each time point. The bars correspond to the standard deviation. The dashed and the solid horizontal lines represent the uncertainty and positivity thresholds, respectively
Fig. 3
Fig. 3
Kinetics of IgM(N), IgG(N) and IgG(S) levels since diagnosis in the total sample and stratified by gender. A, C and E show the LOESS regression models, connecting datapoints belonging to the same participants. B, D and F show the estimated non-linear mixed-effect (NLME) model curves. Each point corresponds to the mean value at each time point. The bars correspond to the standard deviation. The dashed and the solid horizontal lines represent the uncertainty and positivity thresholds, respectively

References

    1. Galit and Seder RGA The power of antibody-based surveillance. N Engl J Med. 2020;383:1782–1784. doi: 10.1056/nejme2029532. - DOI - PMC - PubMed
    1. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80-). 2021 doi: 10.1126/science.abf4063. - DOI - PMC - PubMed
    1. Trinité B, Tarrés-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci Rep. 2021 doi: 10.1038/s41598-021-81862-9. - DOI - PMC - PubMed
    1. Carrillo J, Izquierdo-Useros N, Ávila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2021;538:187–191. doi: 10.1016/j.bbrc.2020.10.108. - DOI - PMC - PubMed
    1. Wang P, Liu L, Nair MS, Yin MT, Luo Y, Wang Q, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020;9:2091–2093. doi: 10.1080/22221751.2020.1823890. - DOI - PMC - PubMed

Associated data